ATXI AVENUE THERAPEUTICS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1644963 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-160.0%
ROA-106.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets104.9%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | — | $0 | $0 | $1.40M | — | $0 |
| R&D expense | $212,000 | $247,000 | $200,000 | $257,000 | $177,000 | $192,000 | $411,000 | $565,000 |
| SG&A expense | $492,000 | $460,000 | $514,000 | $698,000 | $547,000 | $915,000 | $1.49M | $1.03M |
| Operating income | -$704,000 | -$707,000 | -$714,000 | -$752,000 | -$724,000 | $297,000 | -$1.91M | -$1.60M |
| Net income | -$691,000 | -$690,000 | -$695,000 | -$709,000 | -$683,000 | $335,000 | -$1.85M | -$1.54M |
| EPS (basic) | -0.20 | -0.21 | -0.21 | — | -0.21 | 0.11 | -0.62 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.52M | $1.94M | $2.42M | $2.85M | $3.71M | $3.33M | $3.50M | $2.59M |
| Total assets | $1.53M | $1.98M | $2.47M | $2.93M | $3.73M | $4.16M | $3.59M | $2.67M |
| Current liabilities | $1.60M | $1.41M | $1.27M | $1.10M | $1.42M | $1.33M | $1.26M | $816,000 |
| Total liabilities | $1.60M | $1.41M | $1.27M | $1.10M | $1.42M | $1.33M | $1.26M | $816,000 |
| Shareholders' equity | -$75,000 | $569,000 | $1.20M | $1.83M | $3.56M | $4.06M | $3.51M | $2.80M |
| Shares outstanding | 3.29M | 3.29M | 3.29M | 3.18M | 3.18M | 3.18M | 3.18M | 2.11M |
| Cash flow statement | ||||||||
| Operating cash flow | -$422,000 | -$475,000 | -$438,000 | -$854,000 | $383,000 | -$176,000 | -$1.19M | -$764,000 |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $2.09M | $761,000 |
| Stock-based compensation | $47,000 | $61,000 | $61,000 | $142,000 | $163,000 | $175,000 | $185,000 | $522,000 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.